Skip to content

A pragmatic randomized controlled trial of the usefulness of Chinese medicine in the treatment of pulmonary nodules

A pragmatic randomized controlled trial of the usefulness of Chinese medicine in the treatment of pulmonary nodules

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000072
Enrollment
Unknown
Registered
2022-07-31
Start date
2022-08-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

Follow-up Group:The follow-up group was reviewed regularly and no herbal treatment was given.
Non-pharmacological Group :The non-pharmacological group was given auricular pressure pills (acupuncture points of lung, liver, endocrine, Shen Men and San Jiao) for 6 months, once every 2 weeks, with
Chinese Medicine Group:The Chinese medicine group was given traditional Chinese medicine for 6 months by syndrome differentiation, one dose twice a day, morning and evening after meals.

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years. (2) Karnofsky score =90. (3) Less than 15 mm pure ground glass/solid component less than 15 mm partially solid pulmonary nodules. (4) Basic normal function of heart, liver, kidney and hematopoietic system. (5) Voluntary participation in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Total number of pulmonary nodules = 10. (2) Patients considered to have pulmonary nodular disease, tuberculosis, intrapulmonary lymph nodes, malignancy, sclerosing angioma, sarcoidosis, or lymphoma. (3) Current symptoms suggestive of lung cancer: unexplained weight loss of more than 6.5 kg in the past 12 months, or unexplained hemoptysis. (4) Patients undergoing treatment with targeted, immune, chemotherapy, radiotherapy, etc. (5) Patients who are receiving anti-inflammatory therapy or within 1 month of the end of anti-inflammatory therapy. (6) Patients whose imaging of non-first detected nodules suggests that the nodules are progressing or resorbing (7) Patients who are children, pregnant women, psychiatric patients, and patients with tumors that have not undergone radical surgery. (8) Patients who are taking other drugs or health food that have an effect on this trial. (9) Those who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Mean diameter of target nodule;Computer calculated volume;Mean diameter of solid components;CT Value;The Effective Rate;

Secondary

MeasureTime frame
Evaluation of TCM syndrome;Assessment of anxiety state;

Countries

China

Contacts

Public ContactLIU RUI

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

drliur@126.com15210975095

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026